FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Northside Hospital, Inc.